Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care
Authors: Martin1; Lim2; Kerry1; Hilton1
Source: Alimentary Pharmacology & Therapeutics, Volume 12, Number 8, August 1998 , pp. 797-805(9)
Publisher: Blackwell Publishing
Abstract:
Background: H2-receptor antagonists and proton pump inhibitors account for approximately 15% of primary care prescribing costs in the UK. Aim: To examine the use of antisecretory drugs in primary care between October 1991 and September 1996. Method: Analysis of prescribing data from an ongoing postal survey performed every 3 months on a rolling quota of 250 UK general practitioners (GPs), identified from a representative sampling frame of 1000 GPs. Results: There were 8811 new courses of proton pump inhibitors and 11 948 new courses of H2-receptor antagonists during this study. The number of new prescriptions for proton pump inhibitors increased by 174.5%, but decreased for H2-receptor antagonists by 12.5%. Proton pump inhibitors were mostly prescribed for reflux disease (52.7%) and H2-receptor antagonists for non-specific dyspepsia (43.6%). Proton pump inhibitors (14.1%) were less likely to be stopped than H2-receptor antagonists (35.3%) overall, and they were less likely to be stopped because of perceived ineffectiveness (5.3%) than H2-receptor antagonists (23.8%). The rate of stopping treatment because of side-effects was about 3% for both classes of drug. Conclusions: Prescribing of proton pump inhibitors has increased sharply each year since 1991. One reason may be that GPs perceive proton pump inhibitors to be more effective than H2-receptor antagonists.Document Type: Original article
DOI: 10.1046/j.1365-2036.1998.00374.x
Affiliations: 1: Division of General Practice and Primary Care, Sixth Floor, Hunter Wing, St George's Hospital Medical School, London, UK, 2: Gastrointestinal Science Research Unit, St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK

Click here for Page Help